Nanomedicine News

RSS

Merrimack MM-398 Study Demonstrates Feasibility of Ferumoxytol Iron Oxide Nanoparticle as a Tumor Imaging Agent

Merrimack Pharmaceuticals, Inc. today announced Phase 1 results from a clinical pilot study demonstrating that ferumoxytol*, an iron oxide nanoparticle, was well tolerated when used as a tumor contrast agent prior to MM-398 treatment. Data from the first cohort of patients in this study were presented at the American Association of Cancer Research Annual Meeting, April 5-9, 2014, in San Diego, California.

9 Apr 2014

Magnetic Nanoparticle Hyperthermia May Hold Promise for Breast Cancer Treatment

In a presentation exploring the promise of magnetic nanoparticle (mNP) hyperthermia in breast cancer treatment, Dartmouth researcher P. Jack Hoopes, DMV, PhD, reviewed preclinical studies conducted at Norris Cotton Cancer Center and discuss plans for early-phase clinical studies in humans at the annual meeting of the American Association for Cancer Research (AACR).

8 Apr 2014

Clinical Data on BIND Therapeutics’ BIND-014 Nanoparticle Drug Candidate Presented at AACR Meeting

BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, announced today that clinical data on its lead drug candidate, BIND-014, were presented at the American Association of Cancer Research (AACR) meeting.

8 Apr 2014

Sorrento to Present Data on Cynviloq-Abraxane PK Study for Ovarian Cancer

Sorrento Therapeutics, Inc. (Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, announced today that it will present data on the comparison of Cynviloq™ and Abraxane® (nab-paclitaxel) pharmacokinetics (PK) from animal studies.

7 Apr 2014

Lasers Trigger Nanoballoons to Release Drugs

Chemotherapeutic drugs excel at fighting cancer, but they're not so efficient at getting where they need to go.

4 Apr 2014

Controlled Rotation of Magnetic Nanoparticles Could Force Tumour Cells to 'Self-Destruct'

Using magnetically controlled nanoparticles to force tumour cells to 'self-destruct' sounds like science fiction, but could be a future part of cancer treatment, according to research from Lund University in Sweden.

4 Apr 2014

Baxter to Acquire Chatham’s Hemophilia Developmental Gene Therapy Programs

Baxter International Inc. and Chatham Therapeutics, LLC, today announced that Baxter has agreed to acquire all of Chatham’s outstanding membership interests. As a result of the transaction, Baxter will acquire Chatham’s developmental gene therapy programs directed toward the development and commercialization of treatments for hemophilia.

4 Apr 2014

Rexahn to Present Poster on RX-21101 Nano-Polymer-Drug Conjugate Systems at AACR Meeting

Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that it will have two poster presentations at the 2014 American Association for Cancer Research (AACR) Annual Meeting. The conference will take place in San Diego, California, on April 5-9, 2014 at the San Diego Convention Center.

3 Apr 2014

Tekmira Reports Positive Results of LNP Technology at Symposium of Filoviruses

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, announced that recent advances in its anti-viral product platform were presented at the 6th International Symposium of Filoviruses, which is taking place in Galveston, Texas from March 30 to April 2, 2014.

3 Apr 2014

pSivida’s Nanotechnology-Based Tethadur Sustained-Release Delivery System to be Discussed at World Ophthalmology Conference

pSivida Corp. , a leader in the development of sustained release products for treating eye diseases, today announced that pSivida’s president and chief executive officer, Dr. Paul Ashton, will discuss pSivida’s Tethadur™ technology designed to provide sustained delivery of biologics at The World Ophthalmology Conference in Tokyo, April 2-6 and at the SMi Inaugural Conference on Biosimilars and Biobetters USA, in Iselin, New Jersey, April 7-8.

From EyePoint Pharmaceuticals, Inc. 2 Apr 2014